BRIGHT MINDS BIOSCIENCES INC.
DRUGNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for DRUG. That does not mean none is planned.
Get an email about DRUG's next catalysts
Track BRIGHT MINDS BIOSCIENCES (DRUG) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
DRUG Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.07 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
BGM0504 Administered
Type 2 Diabetes Mellitus (T2DM)
BMB-101
Absence Epilepsy
BGM0504
Overweight or Obesity
BGM0504 Administered SC
Type 2 Diabetes
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BGM0504 Administered | Phase 3 | Type 2 Diabetes Mellitus (T2DM) | - | - |
BMB-101 | Phase 2 | Absence Epilepsy | - | - |
BGM0504 | Phase 2 | Overweight or Obesity | - | - |
BGM0504 Administered SC | Phase 2 | Type 2 Diabetes | - | - |
Frequently asked questions
What is in BRIGHT MINDS BIOSCIENCES INC.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in BRIGHT MINDS BIOSCIENCES INC.'s (DRUG) pipeline across Phase 3, Phase 2. Its lead program is BGM0504 Administered (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BRIGHT MINDS BIOSCIENCES INC.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for BRIGHT MINDS BIOSCIENCES INC. (DRUG) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track DRUG biotech catalysts?→
Add DRUG to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BRIGHT MINDS BIOSCIENCES INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.